NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
2024年4月17日 - 7:59PM
ビジネスワイヤ(英語)
Growth driven by efficient Avenova®
direct-to-consumer e-marketing programs
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports
preliminary net revenue for its eyecare and wound care business for
the first quarter of 2024 of $2.6 million, a 13% increase from the
first quarter of 2023. This increase was achieved with lower sales
and marketing expenses, and is attributed primarily to social media
marketing programs aimed at consumer sales of the Company’s lead
product, Avenova Antimicrobial Lid & Lash Solution.
“We started 2024 with strong revenue growth from our core
eyecare business while reducing marketing spend by capitalizing on
our e-marketing expertise,” said Justin Hall, CEO of NovaBay.
“Investing in direct-to-consumer marketing to leverage our clinical
pedigree is a modern approach to the pharmaceutical industry’s
traditional sales model. We are pleased that our social media
programs are efficiently establishing consumer trust in the Avenova
brand as eyecare professionals engage with new potential customers
to share their personal experience, knowledge and
recommendations.”
NovaBay also announces the expansion of its Avenova Ambassador
initiative, an efficient omni-channel, influencer-based social
media program. This initiative involves content collaborations and
affiliate partnerships with key medical influencers including
optometrists and ophthalmologists, collectively known as Avenova
“Docfluencers,” as well as consumer-based influencers in strategic
growth categories such as beauty and health and wellness. The
Avenova Ambassador initiative is proven to be successful in
reaching new customers while helping build brand awareness and
loyalty via social media channels including TikTok, Instagram,
YouTube, Facebook and Pinterest, as well as in email campaigns.
About NovaBay Pharmaceuticals, Inc.
NovaBay’s leading product Avenova® Antimicrobial Lid & Lash
Solution is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is available directly to
consumers through online distribution channels such as Amazon.com.
It is clinically proven to kill a broad spectrum of bacteria to
help relieve the symptoms of bacterial dry eye, yet is
non-irritating and completely safe for regular use. NovaBay offers
a full portfolio of scientifically developed products for each step
of the standard dry eye treatment regimen, including the Avenova
Eye Health Support antioxidant-rich oral supplement, Avenova
Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress
to soothe the eyes and the i-Chek by Avenova to monitor physical
eyelid health. The Avenova Allograft, an amniotic tissue
prescription-only product, is available through eyecare
professionals in the United States.
Forward-Looking Statements
This release contains information about management's view of the
Company's future expectations, plans and prospects that constitute
forward-looking statements within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements can be identified by the fact that they
do not relate strictly to historic or current facts. Such
forward-looking statements are based upon management’s current
expectations, assumptions, estimates, projections and beliefs.
These statements include, but are not limited to, statements
regarding our business strategies, commercial progress, current and
potential future sales channels, and any future revenue, and the
timing of such revenue, that may result from these marketing
efforts, as well as generally the Company’s expected future
financial results. These statements involve risks, uncertainties
and other factors that may cause actual results or achievements to
be materially different and adverse from those expressed in or
implied by these forward-looking statements. Factors that might
cause or contribute to such differences include, but are not
limited to, risks and uncertainties relating to the size of the
potential market for our products, the Company’s products not being
able to penetrate one or more targeted markets and the Company’s
ability to continue as a going concern and revenues (or the
execution on capital raise opportunities) not being sufficient to
meet the Company’s cash needs. Other risks relating to NovaBay’s
business, including risks that could cause results to differ
materially from those projected in the forward-looking statements
in this press release, are detailed in NovaBay’s latest Form 10-K/Q
filings with the Securities and Exchange Commission, especially
under the heading “Risk Factors.” The forward-looking statements in
this release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on X
Connect with NovaBay on LinkedIn Visit NovaBay’s Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240417196687/en/
NovaBay Justin Hall Chief
Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor LHA Investor
Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 4 2024 まで 5 2024
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 5 2023 まで 5 2024